Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

CombiDiag Peripheral Biomarker Based Combinatorial Early Diagnostics for Dementia

Coordinator
Universitatsmedizin Rostock, Germany
Runs
1 February 2023 to 31 July 2027
Status
Running
EU funding
€2.2m
Total cost
—
Partners
22 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101071485

What the project is doing

In the project's own words, from its summary on CORDIS.

CombiDiag DN aims to develop an AI-data-driven peripheral biomarker based combinatorial diagnostic protocol for early stages of Alzheimers disease (AD), a major form of dementia, and to train a new generation of fellows for this interdisciplinary field. Dementia, a devastating disease of older age, is the challenge of our lifetime and one of the Societal Challenges listed by the UN Sustainable Development Goals and Horizon Europe.

CombiDiag responds to this challenge to establish a much-needed DN to carry out an integrated study of minimally invasive and cost-effective peripheral biomarkers, including body fluid markers from blood, urine and saliva, and digital markers from speech, motor functions and sleep for developing the combinatorial early AD diagnostics. The consortium comprises nine academic and eight non-academic institutions across Europe, USA, Canada, and China.

It synergises leading academic and industrial experts worldwide to build a triple-i research and training platform for the training of a new generation of Fellows to take early AD diagnostic research to a new level. Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the CombiDiag platform for triple-i scientific and transferable skills as well as personal quality, creative thinking, and business mind-set.

The DN has a highly innovative research programme for the discovery of peripheral AD biomarkers, detection techniques, AI/data driven technology, clinical validation, and integration into trial designs. The advances in CombiDiag research will enable a case finding tool at primary care level for helping achieve improved drug discoveries, disease-modifying treatments, preventive strategies and care provision for AD. CombiDiag will deliver 10 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

Who is involved

OrganisationCityCountryRole
Universitatsmedizin RostockRostockGermanyCoordinator
G.tec Medical Engineering GmbHSchiedlbergAustriaAssociatedpartner
University of WaterlooWaterlooCanadaAssociatedpartner
Bgi Shenzhen Life Science Research InstitutionShenzhenChinaAssociatedpartner
Capital Medical UniversityBeijingChinaAssociatedpartner
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Ki Elements GmbHSaarbruckenGermanyAssociatedpartner
Universitat Des SaarlandesSaarbruckenGermanyAssociatedpartner
Universitat RostockRostockGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkAssociatedpartner
Nordic Bioscience A/sHerlevDenmarkParticipant
Instituto De Salud Carlos IiiMadridSpainParticipant
Universidad Complutense De MadridMadridSpainAssociatedpartner
FiralisHuningueFranceParticipant
Universite Cote D'azurNiceFranceParticipant
Universita Degli Studi Di Roma La SapienzaRomaItalyParticipant
Alzheimer EuropeSenningerbergLuxembourgAssociatedpartner
Istanbul Medipol UniversitesiIstanbulTürkiyeAssociatedpartner
D Young & Co LLPSouthamptonUnited KingdomAssociatedpartner
The University of ReadingReadingUnited KingdomAssociatedpartner
University of PlymouthPlymouthUnited KingdomAssociatedpartner
Quanterix CorporationLexingtonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI